DURGA-1
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
Near Add Your Location
Sorting 33 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Accepting patients
- Accepting patients
- Accepting patients
Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
- Accepting patients
The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
- Accepting patients
Mayo Clinic (Arizona)
Phoenix, AZ
- Accepting patients
- Accepting patients
St. David's South Austin Medical Center
Austin, TX
- Accepting patients
Massachusetts General Hospital
Boston, MA
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.